[go: up one dir, main page]

DE60123225D1 - Clathratekomplexe auf der basis von hyaluronsäurederivaten und deren verwendung als arzneimittel - Google Patents

Clathratekomplexe auf der basis von hyaluronsäurederivaten und deren verwendung als arzneimittel

Info

Publication number
DE60123225D1
DE60123225D1 DE60123225T DE60123225T DE60123225D1 DE 60123225 D1 DE60123225 D1 DE 60123225D1 DE 60123225 T DE60123225 T DE 60123225T DE 60123225 T DE60123225 T DE 60123225T DE 60123225 D1 DE60123225 D1 DE 60123225D1
Authority
DE
Germany
Prior art keywords
medicaments
hyaluronic acid
acid derivatives
complexes based
clathrate complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60123225T
Other languages
English (en)
Other versions
DE60123225T2 (de
Inventor
Ladislav Soltes
Bohumil Steiner
Eva Machova
Grigorij Kogan
Slavomir Bystricky
Raniero Mendichi
Viktor Bauer
Mojmir Mach
Juraj Alfoeldi
Eva Stratilova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia Farmaceutici SpA
SLOVAK ACAD SCI INST EX PHARM
Original Assignee
Fidia Farmaceutici SpA
SLOVAK ACAD SCI INST EX PHARM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici SpA, SLOVAK ACAD SCI INST EX PHARM filed Critical Fidia Farmaceutici SpA
Application granted granted Critical
Publication of DE60123225D1 publication Critical patent/DE60123225D1/de
Publication of DE60123225T2 publication Critical patent/DE60123225T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60123225T 2000-03-10 2001-03-12 Clathratekomplexe auf der basis von hyaluronsäurederivaten und deren verwendung als arzneimittel Expired - Lifetime DE60123225T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SK358002000 2000-03-10
SK358-2000A SK282717B6 (sk) 2000-03-10 2000-03-10 Spôsob prípravy ultravysokomolekulových hyalurónanov
PCT/EP2001/002722 WO2001066601A1 (en) 2000-03-10 2001-03-12 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals

Publications (2)

Publication Number Publication Date
DE60123225D1 true DE60123225D1 (de) 2006-11-02
DE60123225T2 DE60123225T2 (de) 2007-09-20

Family

ID=20435814

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60123225T Expired - Lifetime DE60123225T2 (de) 2000-03-10 2001-03-12 Clathratekomplexe auf der basis von hyaluronsäurederivaten und deren verwendung als arzneimittel

Country Status (13)

Country Link
US (1) US7563824B2 (de)
EP (1) EP1272530B1 (de)
JP (1) JP2003525980A (de)
AU (2) AU2001252180B2 (de)
CA (1) CA2402421C (de)
CZ (1) CZ20023029A3 (de)
DE (1) DE60123225T2 (de)
ES (1) ES2272465T3 (de)
HU (1) HUP0300163A3 (de)
NO (1) NO330340B1 (de)
PL (1) PL204330B1 (de)
SK (1) SK282717B6 (de)
WO (1) WO2001066601A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
JP2004018750A (ja) * 2002-06-18 2004-01-22 Seikagaku Kogyo Co Ltd 親水性を向上したヒアルロン酸誘導体の製造方法
PT2277551E (pt) 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
RU2005114007A (ru) 2002-10-09 2005-10-10 Инсерт Терапьютикс, Инк. (Us) Материалы на основе циклодекстринов, их композиции и применение
WO2004060404A1 (ja) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha 薬物担体
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
EP1884231A1 (de) * 2006-08-01 2008-02-06 Auriga International S.A. Kosmetische oder Pharmazeutische Zusammensetzung, die Hyaluronsäure enthält
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US8966080B2 (en) * 2007-04-13 2015-02-24 Emc Corporation Systems and methods of managing resource utilization on a threaded computer system
US8658148B2 (en) 2007-06-22 2014-02-25 Genzyme Corporation Chemically modified dendrimers
US8211450B2 (en) 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
US9018193B2 (en) 2010-09-13 2015-04-28 Bev-Rx, Inc. Aqueous drug delivery system
US9590913B2 (en) 2011-02-07 2017-03-07 LiveQoS Inc. System and method for reducing bandwidth usage of a network
KR101383941B1 (ko) * 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
KR20160020509A (ko) * 2013-06-14 2016-02-23 갈데르마 소시에떼아노님 가교된 히알루론산 및 사이클로덱스트린을 포함하는 조성물
ITMI20132116A1 (it) * 2013-12-18 2015-06-19 Apharm Srl Associazione di glicosamminoglicani e ciclodestrine
CN105153481B (zh) * 2015-10-16 2017-06-16 南开大学 一种荧光超分子纳米粒子及其制备方法和应用
US10988600B2 (en) 2016-06-23 2021-04-27 Galderma Holding SA Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof
CN106491526B (zh) * 2016-11-14 2019-03-22 暨南大学 一种药物缓释型复合滴眼液及其制备方法与应用
CN106759942B (zh) * 2017-03-01 2022-07-01 邓剑涛 一种一体固化的无焊接销锁连接结构及其施工方法
IT201800007683A1 (it) 2018-07-31 2020-01-31 Altergon Sa Composizioni cooperative sinergiche utili per aumento del tessuto molle, rilascio di farmaco e campi correlati
IT201800009444A1 (it) * 2018-10-15 2020-04-15 Fidia Farm Spa Coniugati tra acido ialuronico e amminobisfosfonati e loro impiego terapeutico
WO2021113986A1 (en) * 2019-12-13 2021-06-17 Folium Labs Inc. Complexes comprising a carbohydrate polymer and an active ingredient and processes for their preparation
CN116806818B (zh) * 2023-05-19 2025-08-29 内蒙古农业大学 超分子杂化水凝胶及其制备方法、农药及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5470512A (en) * 1990-05-24 1995-11-28 Nippon Kayaku Kabushiki Kaisha Process for producing microcapsules
FR2665158B1 (fr) * 1990-07-30 1993-12-24 Air Liquide Clathrates de peroxyacides.
US5690961A (en) * 1994-12-22 1997-11-25 Hercules Incorporated Acidic polysaccharides crosslinked with polycarboxylic acids and their uses

Also Published As

Publication number Publication date
NO20024192D0 (no) 2002-09-03
CA2402421A1 (en) 2001-09-13
AU2001252180B2 (en) 2005-06-30
NO330340B1 (no) 2011-03-28
PL204330B1 (pl) 2010-01-29
EP1272530B1 (de) 2006-09-20
CZ20023029A3 (cs) 2003-04-16
NO20024192L (no) 2002-09-03
SK3582000A3 (en) 2002-09-10
PL357557A1 (en) 2004-07-26
HUP0300163A2 (hu) 2003-06-28
ES2272465T3 (es) 2007-05-01
CA2402421C (en) 2009-12-22
US20040076680A1 (en) 2004-04-22
EP1272530A1 (de) 2003-01-08
WO2001066601A1 (en) 2001-09-13
SK282717B6 (sk) 2002-11-06
DE60123225T2 (de) 2007-09-20
WO2001066601A8 (en) 2002-01-03
JP2003525980A (ja) 2003-09-02
HUP0300163A3 (en) 2003-09-29
US7563824B2 (en) 2009-07-21
AU5218001A (en) 2001-09-17

Similar Documents

Publication Publication Date Title
DE60123225D1 (de) Clathratekomplexe auf der basis von hyaluronsäurederivaten und deren verwendung als arzneimittel
ATE438639T1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
DE50112669D1 (de) Acridin-derivate und deren verwendung als arzneimittel
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
CY2015009PI2 (el) Ινδολινονες υποκατεστημενες στη θεση 6, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
ATE469152T1 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
ATE466011T1 (de) Pyrazol-derivate, ihre herstellung und ihre verwendung in arzneimitteln
DE60138768D1 (de) Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
DE60123210D1 (de) Picolinsäure-derivate und ihre verwendung als fungizide
ATE299503T1 (de) Pyridin-3-carbonsäurederivate und ihre verwendung als zwischenprodukte
DE60045321D1 (de) Mutilinderivate und deren Verwendung als antimikrobielle Agenzien
DE60141603D1 (de) Neue mandelsäurederivate und deren verwendung als thrombininhibitoren
ATE522213T1 (de) Fünfgliedrige-heteroringderivate , ihre herstellung und ihre verwendung als arzneimittel
ATE248169T1 (de) 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate
SI1165516T1 (sl) Heterociklična sečnina in sorodne spojine, uporabne kot protivnetna sredstva
ATE299148T1 (de) Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
DE60034713D1 (de) Chinolyl-propyl-piperidinderivate und deren Verwendung als antimikrobielle Wirkstoffe
ATE319684T1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DE50008597D1 (de) Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
DE59905572D1 (de) Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
DE69927033T2 (de) 4-aminopyridinderivate, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
DE50003761D1 (de) Indeno-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel
DE60009155D1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
ATE323694T1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
ATE255592T1 (de) Streptograminderivate, ihre herstellung und sie enthaltende zubereitungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition